PD 404,182 is a virocidal small molecule that disrupts hepatitis C virus and human immunodeficiency virus

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 2, 2012, Pages 672-681

  Chamoun, Ana Maria ^a   Chockalingam, Karuppiah ^a   Bobardt, Michael ^c   Simeon, Rudo ^a   Chang, Jinhong ^d   Gallay, Philippe ^c   Chen, Zhilei ^a,b  

^a Texas AandM University   (United States)

^b TEXAS A AND M UNIVERSITY   (United States)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

^d DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; LIPID; LIPOSOME; NUCLEIC ACID; PD 404182; UNCLASSIFIED DRUG;

ARTICLE; CELL CONTACT; CELL CULTURE; CELL FREE SYSTEM; CELL LINE; CONTROLLED STUDY; CYTOTOXICITY; DENGUE VIRUS; DRUG EFFECT; DRUG EXPOSURE; DRUG POTENCY; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; IC 50; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; SERUM; SEXUAL INTERCOURSE; SIMIAN IMMUNODEFICIENCY VIRUS; SINDBIS VIRUS; TEMPERATURE; TIME; VIRION; VIRUS ATTENUATION; VIRUS ENVELOPE; VIRUS INACTIVATION; VIRUS ISOLATION; VIRUS TRANSMISSION;

ANIMALS; ANTIVIRAL AGENTS; CELL LINE, TUMOR; HEPACIVIRUS; HIV-1; HIV-2; HUMANS; INHIBITORY CONCENTRATION 50; LIVER; MICROBIAL SENSITIVITY TESTS; SIMIAN IMMUNODEFICIENCY VIRUS; SMALL MOLECULE LIBRARIES;

EID: 84862914904     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05722-11     Document Type: Article

References (48)

1. Aiken C, Troro D. 1995. Nef stimulates human immunodeficiency virus type 1 proviral RNA synthesis. J. Virol. 69:5048-5056.
2. Birck MR, Holler TP, Woodard RW. 2000. Identification of a slow tight-binding inhibitor of 3-deoxy-D-manno-octulosonic acid 8-phosphate synthase. J. Am. Chem. Soc. 122:9334-9335.
3. Bobardt MD, Chatterji U, Schaffer L, de Witte L, Gallay PA. 2010. Syndecan-Fc hybrid molecule as a potent in vitro microbicidal anti-HIV-1 agent. Antimicrob. Agents Chemother. 54:2753-2766.
4. Bobardt MD, et al. 2008. Hepatitis C virus NS5A anchor peptide disrupts human immunodeficiency virus. Proc. Natl. Acad. Sci. U. S. A. 105:5525-5530. (Pubitemid 351753896)
5. Bremer CM, Bung C, Kott N, Hardt M, Glebe D. 2009. Hepatitis B virus infection is dependent on cholesterol in the viral envelope. Cell Microbiol. 11:249-260.
6. Cannon PM, Kim N, Kingsman SM, Kingsman AJ. 1996. Murine leukemia virus-based Tat-inducible long terminal repeat replacement vectors: a new system for anti-human immunodeficiency virus gene therapy. J. Virol. 70:8234-8240. (Pubitemid 26339145)
7. CDC. 2006. The global HIV/AIDS pandemic, 2006. MMWR Morb. Mortal. Wkly. Rep. 55:841-844.
8. Cheng G, et al. 2008. A virocidal amphipathic alpha-helical peptide that inhibits hepatitis C virus infection in vitro. Proc. Natl. Acad. Sci. U. S. A. 105:3088-3093. (Pubitemid 351723672)
9. Chockalingam K, Simeon RL, Rice CM, Chen Z. 2010. A cell protection screen reveals potent inhibitors of multiple stages of the hepatitis C virus life cycle. Proc. Natl. Acad. Sci. U. S. A. 107:3764-3769.
10. Cowan S, et al. 2002. Cellular inhibitors with Fv1-like activity restrict human and simian immunodeficiency virus tropism. Proc. Natl. Acad. Sci. U. S. A. 99:11914-11919. (Pubitemid 34994498)
11. Deming P, McNicholl IR. 2011. Coinfection with human immunodeficiency virus and hepatitis C virus: challenges and therapeutic advances insights from the society of infectious diseases pharmacists. Pharmacotherapy 31:357-368.
12. Dhawan D, Mayer KH. 2006. Microbicides to prevent HIV transmission: overcoming obstacles to chemical barrier protection. J. Infect. Dis. 193:36-44. (Pubitemid 43032496)
13. Enserink M. 2011. Infectious diseases. First specific drugs raise hopes for hepatitis C. Science 332:159-160.
14. Evans MJ, et al. 2007. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 446:801-805. (Pubitemid 46582027)
15. Ganesh L, et al. 2004. Infection of specific dendritic cells by CCR5-tropic human immunodeficiency virus type 1 promotes cell-mediated transmission of virus resistant to broadly neutralizing antibodies. J. Virol. 78:11980-11987. (Pubitemid 39390783)
16. Geijtenbeek TB, et al. 2000. DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell 100:587-597.
17. Günther-Ausborn S, Praetor A, Stegmann T. 1995. Inhibition of influenza-induced membrane fusion by lysophosphatidylcholine. J. Biol. Chem. 270:29279-29285.
18. Guo H, et al. 2011. Alkylated porphyrins have broad antiviral activity against hepadnaviuses, flaviviruses, filoviruses and arenaviruses. Antimicrob. Agents Chemother. 55:478-486.
19. Henchal EA, Putnak JR. 1990. The dengue viruses. Clin. Microbiol. Rev. 3:376-396.
20. Isojima Y, et al. 2009. CKIepsilon/delta-dependent phosphorylation is a temperature-insensitive, period-determining process in the mammalian circadian clock. Proc. Natl. Acad. Sci. U. S. A. 106:15744-15749.
21. Jose J, Snyder JE, Kuhn RJ. 2009. A structural and functional perspective of alphavirus replication and assembly. Future Microbiol. 4:837-856.
22. Kalén M, et al. 2009. Combination of reverse and chemical genetic screens reveals angiogenesis inhibitors and targets. Chem. Biol. 16:432-441.
23. Klasse PJ, Shattock R, Moore JP. 2008. Antiretroviral drug-based microbicides to prevent HIV-1 sexual transmission. Annu. Rev. Med. 59:455-471. (Pubitemid 351287949)
24. Kolykhalov AA, Mihalik K, Feinstone SM, Rice CM. 2000. Hepatitis C virus-encoded enzymatic activities and conserved RNA elements in the 3′nontranslated region are essential for virus replication in vivo. J. Virol. 74:2046-2051. (Pubitemid 30434065)
25. Lederman MM, Offord RE, Hartley O. 2006. Microbicides and other topical strategies to prevent vaginal transmission of HIV. Nat. Rev. Immunol. 6:371-382.
26. Li Y, et al. 2006. Characterization of antibody responses elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope glycoproteins in selected adjuvants. J. Virol. 80:1414-1426. (Pubitemid 43134099)
27. Lindenbach BD, et al. 2005. Complete replication of hepatitis C virus in cell culture. Science 309:623-626. (Pubitemid 41033648)
28. Martin I, Ruysschaert JM. 1995. Lysophosphatidylcholine inhibits vesicles fusion induced by the NH2-terminal extremity of SIV/HIV fusogenic proteins. Biochim. Biophys. Acta 1240:95-100.
29. Marukian S, et al. 2008. Cell culture-produced hepatitis C virus does not infect peripheral blood mononuclear cells. Hepatology 48:1843-1850.
30. Morizono K, Bristol G, Xie YM, Kung SK, Chen IS. 2001. Antibody-directed targeting of retroviral vectors via cell surface antigens. J. Virol. 75:8016-8020. (Pubitemid 32743673)
31. Moss B. 2006. Poxvirus entry and membrane fusion. Virology 344:48-54. (Pubitemid 41814449)
32. Operskalski EA, Kovacs A. 2011. HIV/HCV co-infection: pathogenesis, clinical complications, treatment, and new therapeutic technologies. Curr. HIV/AIDS Rep. 8:12-22.
33. Pietschmann T, et al. 2006. Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. Proc. Natl. Acad. Sci. U. S. A. 103:7408-7413. (Pubitemid 43727846)
34. Pillay D. 2007. The priorities for antiviral drug resistance surveillance and research. J. Antimicrob. Chemother. 60(Suppl. 1):i57-i58.
35. Platt EJ, Wehrly K, Kuhmann SE, Chesebro B, Kabat D. 1998. Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J. Virol. 72:2855-2864. (Pubitemid 28175522)
36. Rando RF, et al. 2006. Critical design features of phenyl carboxylate-containing polymer microbicides. Antimicrob. Agents Chemother. 50:3081-3089. (Pubitemid 44396415)
37. Reed LJ, Muench H. 1938. A simple method of estimating fifty percent end-points. Am. J. Hyg. (London) 27:493-497.
38. Reesink HW, et al. 2006. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. Gastroenterology 131:997-1002. (Pubitemid 44498690)
39. Rice CM, Levis R, Strauss JH, Huang HV. 1987. Production of infectious RNA transcripts from Sindbis virus cDNA clones: mapping of lethal mutations, rescue of a temperature-sensitive marker, and in vitro mutagenesis to generate defined mutants. J. Virol. 61:3809-3819. (Pubitemid 18011479)
40. Shattock RJ, Moore JP. 2003. Inhibiting sexual transmission of HIV-1 infection. Nat. Rev. Microbiol. 1:25-34.
41. Shepard CW, Finelli L, Alter MJ. 2005. Global epidemiology of hepatitis C virus infection. Lancet Infect. Dis. 5:558-567. (Pubitemid 41196755)
42. Soares MM, King SW, Thorpe PE. 2008. Targeting inside-out phosphatidylserine as a therapeutic strategy for viral diseases. Nat. Med. 14:1357-1362.
43. St. Vincent MR, et al. 2010. Rigid amphipathic fusion inhibitors, small molecule antiviral compounds against enveloped viruses. Proc. Natl. Acad. Sci. U. S. A. 107:17339-17344.
44. Susser S, et al. 2009. Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. Hepatology 50:1709-1718.
45. Takeuchi T, et al. 1999. Real-time detection system for quantification of hepatitis C virus genome. Gastroenterology 116:636-642. (Pubitemid 29106771)
46. Welsch S, et al. 2009. Composition and three-dimensional architecture of the dengue virus replication and assembly sites. Cell Host Microbe 5:365-375.
47. Wolf MC, et al. 2010. A broad-spectrum antiviral targeting entry of enveloped viruses. Proc. Natl. Acad. Sci. U. S. A. 107:3157-3162.
48. Zennou V, Bieniasz PD. 2006. Comparative analysis of the antiretroviral activity of APOBEC3G and APOBEC3F from primates. Virology 349:31-40.